GPGiulia Pavia

Giulia Pavia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giulia Pavia has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases

    by Luigi Gargiulo, Carlo Alberto Vignoli, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Chiara Perugini

    Citation: Gargiulo L, Vignoli CA, Pavia G, Narcisi A, Costanzo A, Perugini C. Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases. Dermatol Pract Concept. 2023;13(2):e2023097. DOI: https://doi.org/10.5826/dpc.1302a97 Accepted: July 27, 2023; Published: April 2023 Copyright: ©2023 Gargiulo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: Antonio Costanzo has been a consultant and/or speaker for Abb-Vie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Galderma, Boehringer, Novartis, Pfizer, Sandoz, and UCB. Alessandra Narcisi has been a consultant and/or speaker for Abb-Vie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Boehringer, Novartis, Pfizer and UCB. Luigi Gargiulo, Carlo Alberto Vignoli, Giulia Pavia and Chiara Perugini have nothing to disclose. Authorship: All authors have contributed significantly to this publication. Corresponding author: Dr. Carlo Alberto Vignoli, MD, Dermatology Unit, Department of Biomedical Sciences, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Itlay. Tel: +39 0282244050 Email: c.alberto.vignoli@gmail.com Keywords : psoriasis, palmoplantar pustular psoriasis, risankizumab, biologics, anti-IL-23 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


  • Open Access

    Sub‐erythrodermic psoriasis successfully treated with bimekizumab: A case report

    by Mario Valenti, Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo


  • Real life long‐term efficacy and safety of ixekizumab in moderate‐to‐severe psoriasis: A 192 weeks multicentric retrospective study— IL PSO ( Italian landscape psoriasis)

    by Piergiorgio Malagoli, Paolo Dapavo, Giulia Pavia, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Giovanni Damiani, Valentina Dini, et al.

    Psoriasis is one of the commonest inflammatory skin diseases determining a very high impact on patients' quality of life and daily activities and relationships. Several biologic therapies have been approved through the years for the treatment of moderate-to-severe plaque psoriasis, and efficacy and safety profile have been analyzed in clinical trials. Ixekizumab is an immunoglobulin G subclass 4 monoclonal antibody that selectively targets and binds IL-17A with high specificity and affinity. Inhibiting IL-17A activity, ixekizumab reduces and turns down levels of inflammation, resulting in the clinical improvement of the disease. Long-term efficacy and safety profile of ixekizumab have been investigated and reported in the UNCOVER trials, but in literature there are only few studies based on real life experience. We present the efficacy and safety profile of ixekizumab in a cohort of 779 patients affected by moderate-to-severe plaque psoriasis and treated with ixekizumab in 11 Italian dermatology hospitals, with a follow-up of care until 192 weeks.


  • Apremilast for the treatment of palmo‐plantar non‐pustular psoriasis: A real‐life single‐center retrospective study

    by Giulia Pavia, Luigi Gargiulo, Andrea Cortese, Mario Valenti, Federica Sanna, Riccardo G. Borroni, Antonio Costanzo, Alessandra Narcisi

    Palmoplantar psoriasis (PP) is a type of psoriasis that involves the skin of the palms and soles and can present as hyperkeratotic, similar to the vulgaris psoriasis of the body. Apremilast, as an oral inhibitor of phosphodiesterase 4 (PDE4), is currently approved for the treatment of psoriatic arthritis and for moderate-to-severe psoriasis in adult patients who have not responded or have contraindications or do not tolerate other systemic treatments. We evaluated the efficacy and safety of apremilast in the treatment of non-pustular palmo-plantar psoriasis in a cohort of 12 patients. We found a clinical response of clear/almost clear palmoplantar psoriasis (PPPGA score 0/1) in 83.33% of our patients, at week 16. No significant safety issues were reported and none of our patients had to discontinue the drug.


  • Anti‐IL17 and anti‐IL23 biologic drugs for scalp psoriasis: A single‐center retrospective comparative study

    by Alessandra Narcisi, Mario Valenti, Andrea Cortese, Francesco Toso, Giulia Pavia, Luigi Gargiulo, Riccardo Borroni, Antonio Costanzo

    Scalp is a frequent localization of psoriasis that has a massive impact on patient's quality of life. Managing this psoriasis' manifestation is often challenging, thus biologic drugs are widely used as a treatment option in refractory scalp psoriasis. The aim of our study is to retrospectively compare the efficacy of anti-interleukin (IL) 23 drugs (guselkumab, tildrakizumab, risankizumab) and anti-IL17 or anti-IL17RA biologics (secukinumab, ixekizumab, and brodalumab) in real-life patients affected by scalp psoriasis. One hundred twenty-seven patients with a clinical diagnosis of scalp psoriasis and a baseline scalp Physician Global Assessment ≥3 were enrolled; 65 patients were treated with anti-IL23 and anti-IL62 with anti-IL17 or anti-IL17RA. Statistical analysis trough χ2 test was performed in order to evaluate the percentage of response among the two groups of patients. Responders' percentage of patients under anti-IL23 was 41.5%, 75.4%, 88.1%, 87.5%, 93.7%, and 100% at Week 4, 16, 48, 96, and 144, respectively. In the group on anti-IL17 was 62.9%, 90.3%, 91.2%, 97.3%, 96.9%, and 95.2% at Week 4, 16, 48, 96, and 144, respectively. Both anti-IL17 and anti-IL23 appeared to be effective on scalp psoriasis; in particular patients treated with anti-IL17 drugs reached a faster significant reduction of the lesions; on the other hand, anti-IL23 monoclonal antibodies were slightly superior in maintaining the clinical improvement through the follow-up.


  • Urticarial rash in autoinflammatory syndromes

    by Paola Facheris, Andrea D’aRino, Giulia Pavia, Mario Valenti, Giacomo M. Guidelli, Riccardo G. Borroni, Antonio Costanzo, Alessandra Narcisi

    Article: Urticarial rash in autoinflammatory syndromes - Italian Journal of Dermatology and Venereology 2021 June;156(3):398-400 - Minerva Medica - Journals


  • Palmar nodules in a young woman with ulcerative colitis and enteropathic arthritis

    by Paola Facheris, Mariangela Allocca, Mario Valenti, Giulia Pavia, Luigi Gargiulo, Sofia A. A. M. Manara, Alessandra Narcisi, Antonio Costanzo, Riccardo G. Borroni

  • Open Access

    Impact of delay in follow‐up due to COVID‐19 pandemic on skin cancer progression: a real‐life experience from an Italian hub hospital

    by Mario Valenti, Giulia Pavia, Luigi Gargiulo, Paola Facheris, Ombretta Nucca, Luca Mancini, Francesco Sacrini, Riccardo G. Borroni, Alessandra Narcisi, Antonio Costanzo

    Background: The COVID‐19 pandemic required the setting of a national lockdown in Italy from March 9, 2020, until May 18, 2020; therefore, most of the non‐COVID‐19 activities were postponed. As a consequence, many follow‐up visits in patients with previously excised skin cancers were delayed. The aim of this retrospective real‐life case–control study is demonstrating that delay in follow‐up led to an increased incidence of advanced melanoma and keratinocyte cancers on the total of surgically excised skin cancers.Methods: The incidence of excised advanced melanoma and keratinocyte cancers in our dermato‐surgery division in the period May 18 to November 18, 2020, was compared to the same time span of 2019. All data were collected from the electronic database of our department. Odds ratio with 95% confidence interval was used to assess the risk of excised advanced skin cancers in 2020 compared to 2019.Results: From May to November 2019, we performed 265 surgical excisions, while during the pandemic in 2020, we completed 280 surgeries. The number of advanced skin cancers excised between May 18 and November 18, 2020, was significantly higher compared with the same period in 2019 (54 vs. 22, OR: 2.64; 95% CI: 1.56–4.47; P = 0.0003). Significant differences were also observed regarding the number of surgically removed advanced BCCs (OR 2.15; 95% CI 1.14–4.07; P = 0.0187) and advanced SCCs (OR 4.60; 95% CI 1.31–16.18; P = 0.0175).Conclusion: These results confirm that delay in follow‐up and, consequently, postponed surgical excisions are related to an increased incidence of advanced skin tumors, resulting in poorer prognosis lifelong. Follow‐up visits should be carried on even during COVID‐19 pandemic, avoiding significant delays as much as possible.


  • Open Access

    Skin cancers: how to balance the risks and benefits of surgery during COVID‐19 pandemic (a Northern Italy single‐center experience)

    by Giulia Pavia, Luigi Gargiulo, Mario Valenti, Paola Facheris, Ombretta Nucca, Alessandra Narcisi, Riccardo G. Borroni, Antonio Costanzo